Date: 2013-12-18
Type of information: R&D agreement
Compound:
Company: Circuit Therapeutics (USA) Boehringer Ingelheim (Germany)
Therapeutic area: CNS diseases - Mental diseases
Type agreement: R&D
Action mechanism:
Disease: psychiatric disorders
Details: * On December 18, 2013, Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors. Circuit Therapeutics\' key technology, optogenetics, allows the control of individual nerve cells and circuits within the brain enabling their functional identification and characterization. The combination of optogenetics and sophisticated molecular technologies provides an unprecedented level of focus to identify novel drug targets and approaches for drug development. The new insights enabled by circuit-based analysis provide fundamentally differentiated approaches to understanding and treating brain disorders, which have otherwise been difficult to address.
Under the terms of the agreement the research and development capabilities of the two companies will be brought together to provide novel avenues for drug discovery in a three-year research program. Further details of the agreement are not disclosed.
Financial terms:
Latest news:
